Earnings
Bayer expects Consumer Health sales for the full year to advance by 1% at best due to increasingly challenging conditions in its two largest markets.
Dental guards already accounted for “well over half of the brand’s revenue” and DenTek claimed more than 50% of US category share when PCH launched "Fantasy Guards" campaign targeting fantasy football league enthusiasts.
Perrigo pauses $240m spending planned for formula business as it considers options to be in better position to boost growth on OTC drugs. “Problems make formula manufacturing’s “long-term fit alongside our faster-growing, higher-cash-yielding consumer health OTC portfolio less strategic,” says presi
With Q3 results, C&D increases full-year forecast for reported sales growth to around 1.5% after guiding 1% in July. Considering options for cutting its losses linked to its slow-selling product line, C&D also adding revenue growth from adding Touchland scented hand sanitizer brand.
Enzymatica says it is taking "longer than we expected" to sign up partners to launch its ColdZyme innovation across North America and Asia.
Haleon delivers organic sales growth of 3.4% in Q3 despite ongoing challenges in the US related to consumer spending.
Other OTC marketers could join Kenvue in submitting comments opposing citizen petition request for label warnings about prenatal exposure to acetaminophen. Firms also will be discussing costs linked to tariffs Trump has imposed on imports from most every country, particularly China and India, and th
Building brands that resonate with consumers is helping Reckitt secure share gains in China's consumer health market.
German CHC firm seeing good growth in its home market after making advertising investments behind key brands like the PureSGP dietary supplement range.
Following a difficult opening to the year given the weak cough & cold season, Stada's Consumer Healthcare business delivers in Q2.
A rapid decline in performance has left Orkla Health's new CEO Mats Palmquist with a big job on his hands to turn around the business.
When consumer health and beauty firms announce results for current quarter, they likely will note trend many reported after first quarter, an uptick in revenues and volume due to consumer concern about Trump’s tariffs gambit leading to higher product prices.
Sweden's Moberg wants to introduce its onychomycosis treatment to the US but expects it will need to complete an additional study to win FDA approval.
Amphastar plans three- to five-year expansion to quadruple production capacity for its US manufacturing operations at its Rancho Cucamonga, CA, headquarters. Primatene Mist Q2 sales reached $22.88m from $22.86m a year ago.
Galenica's Swiss consumer health business Verfora is reaping the rewards of its expansion in the complementary medicine market with a solid showing in the first half of the year.
PCH lowers full-year guidance even after reaching $100m deal to acquire Canadian sterile ophthalmic manufacturer for its Clears Eyes line troubled by supply slumps for several years. Its $47.5m reported net sales for April-June period were down 6% from a year ago.
Three weeks into his appointment as interim CEO, Kirk Perry sets priorities including “reduce organizational complexity,” “reinforce a consumer-centric mindset” and “refocus on household penetration.”
Like its peers, Bayer Consumer Health has struggled in the challenging US market in the first half of 2025 and says it doesn't expect conditions to change this year.
“We continue to grow the brand. It was slower than initially anticipated or forecasted in basis, but I'm pleased with how it's developing,” says CEO Patrick Lockwood-Taylor of Opill performance.
OTC sales grew at Italy's Recordati in the first half of 2025, with an improving cough and cold picture contributing to the rise.